Massive advances in computational power have – particularly in the last few years – greatly improved the impact that molecular modelling can have on drug discovery projects. These advances mark the start of a new era in quantitatively accurate free-energy calculations, giving researchers unprecedented insight into the factors controlling ligand binding, selectivity, solubility and overall structure–activity relationship (SAR).
State-of-the-art collaborative informatics platforms, including Schrödinger’s LiveDesign, allow exciting opportunities for progress. These include immediate communication between experts across project disciplines, allowing the full range of an organisation’s experience to aid critical design issues.
In this webinar including a presentation from research fellow Daniel Robinson, Schrödinger principal scientist Jas Bhachoo uses a case study to discuss how modelling solutions can help drive drug discovery programs forward.
By the end of this webinar you will:
- Have learned how Schrödinger’s advanced computational platform can accelerate your drug discovery R&D projects
- Have discovered how free-energy calculations are giving researchers unprecedented insight into the factors controlling ligand binding, selectivity, solubility and overall SAR
- Understand how Schrödinger’s enterprise software LiveDesign is revolutionising communication and collaboration within drug discovery project teams
This webinar is brought in association with Schrödinger.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Founded in 1990, Schrödinger has nearly 400 employees and operations across the world. For more information, please visit www.schrodinger.com
Speaker: Jas Bhachoo, Principal Scientist, Schrödinger
